Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endosialin, also known as Tumor Endothelial Marker 1 (TEM1) or CD248, is a transmembrane glycoprotein highly expressed in the tumor stroma, particularly in cancer-associated fibroblasts and pericytes. It plays a role in promoting tumor progression through enhancing cell adhesion, migration, and proliferation, stimulating angiogenesis, and inducing an immunosuppressive microenvironment. Due to its restricted expression outside tumors, it is considered an attractive target for anti-cancer therapy.
Antibody-mediated internalization and disruption of vessel function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endosialin (None).